Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
Ann. hepatol ; 16(1): 123-132, Jan.-Feb. 2017. graf
Article Dans Anglais | LILACS | ID: biblio-838094

Résumé

Abstract: Introduction and aim. Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free wáter excretion, but its efficacy and safety in cirrhotic patients remain unclear. Material and methods. We studied the usage and safety of tolvaptan in cirrhotic patients in a real-life, non-randomized, multicenter prospective cohort study. Forty-nine cirrhotic patients with hyponatremia were treated with tolvaptan 15 mg daily, and 48 patients not treated with tolvaptan in the same period served as controls. Improvement in serum sodium level was defined as an increase in serum sodium from < 125 to ≥ 125 mmol/L or from 125-134 to ≥ 135 mmol/L on day 7. Results. Twenty-three (47%) patients in the tolvaptan group and 17 (35%) in the control group had normal serum sodium on day 7 (p = 0.25). Serum sodium improved in 30 (61%) patients in the tolvaptan group and 17 (35%) patients in the control group (p = 0.011). Adverse events occurred in 46-47% of patients in both groups, and tolvaptan was not associated with worsened liver function. No patient with normal serum sodium on day 7 died within 30 days of treatment, whereas 16% of those with persistent hyponatremia died (p = 0.0019). Conclusion. In conclusion, short-term tolvaptan treatment is safe and can improve serum sodium level in cirrhotic patients with hyponatremia. Normalization of serum sodium level is associated with better survival.


Sujets)
Humains , Adulte d'âge moyen , Sujet âgé , Sodium/sang , Benzazépines/usage thérapeutique , Antagonistes des récepteurs de l'hormone antidiurétique/usage thérapeutique , Hyponatrémie/traitement médicamenteux , Cirrhose du foie/complications , Facteurs temps , Benzazépines/effets indésirables , Marqueurs biologiques/sang , Études cas-témoins , Chine , Études prospectives , Facteurs de risque , Résultat thérapeutique , Estimation de Kaplan-Meier , Antagonistes des récepteurs de l'hormone antidiurétique/effets indésirables , Tolvaptan , Hyponatrémie/étiologie , Hyponatrémie/mortalité , Hyponatrémie/sang , Cirrhose du foie/diagnostic , Cirrhose du foie/mortalité
2.
Braz. j. infect. dis ; 19(4): 417-425, July-Aug. 2015. ilus
Article Dans Anglais | LILACS | ID: lil-759277

Résumé

Natural killer cells are a unique type of lymphocytes with cytotoxic capacity, and play important roles against tumors and infections. Recently, natural killer cells have been increasingly valued in their effects in hepatitis B virus infection. Since hepatitis B virus is not cytopathic, the subsequent antiviral immune responses of the host are responsible for sustaining the liver injury, which may result in cirrhosis and even hepatocellular carcinoma. Many studies have confirmed that natural killer cells participate in anti-hepatitis B virus responses both in the early phase after infection and in the chronic phase viacytolysis, degranulation, and cytokine secretion. However, natural killer cells play dichotomic roles: they exert antiviral and immunoregulatory functions whilst contribute to the pathogenesis of liver injury. Here, we review the roles of natural killer cells in hepatitis B virus infection, introducing novel therapeutic strategies for controlling hepatitis B virus infection viathe modulation of natural killer cells.


Sujets)
Humains , Hépatite B/immunologie , Cellules tueuses naturelles/immunologie , Illustration médicale
SÉLECTION CITATIONS
Détails de la recherche